Takayasu’s arteritis progression on anti-TNF biologics: a case series-Reference-Cited by-同舟云学术

Takayasu’s arteritis progression on anti-TNF biologics: a case series

Published:2011-01-11 Issue:5 Volume:30 Page:703-706
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Osman Mohammed,Aaron Stephen,Noga Michelle,Yacyshyn Elaine

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s10067-010-1658-1.pdf

Reference18 articles.

1. Baumgart DC, Sandborn WJ (2007) Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369(9573):1641–5167

2. Reny JL et al (2003) Association of Takayasu’s arteritis and Crohn’s disease: results of a study on 44 Takayasu patients and review of the literature. Ann Med Interne (Paris) 154(2):85–90

3. Chung SA, Seo P (2009) Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 21(1):3–9

4. Maffei S et al (2009) Refractory Takayasu arteritis successfully treated with infliximab. Eur Rev Med Pharmacol Sci 13(1):63–65

5. Molloy ES et al (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67(11):1567–1569

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis;Pharmaceuticals;2024-08-05

2. Simultaneous Presentation of Takayasu Arteritis and Crohn’s Disease in a Middle-Aged Patient: Are they two sides of the same coin?;BMJ Case Reports;2024-03

3. Takayasu’s arteritis associated with Crohn’s disease treated with infliximab;Clinical Journal of Gastroenterology;2024-01-05

4. Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study;RMD Open;2023-06

5. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study;RMD Open;2023-06